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Abstract
Early cancer detection and suitable treatment improve the 5-year survival rates of lung
cancer significantly. Many cancer diagnostic approaches have been investigated, includ-
ing mammography, magnetic resonance imaging, ultrasound, computerized tomogra-
phy, positron emission tomography and biopsy. However, these techniques have some
drawbacks such as expensive and time-consuming. Electromagnetic tomography (EMT)
has been proposed as a promising diagnostic tool for lung cancer detection. In addition,
developing label-free and cost-effective biosensors for target tumor markers detection
have attracted attentions worldwide. This chapter reviews the recently developed EMT
and bio-sensing techniques for early-stage lung cancer detection.
Keywords: biomedical imaging, biomarker, biosensor, lung cancer, nanoparticles,
electromagnetic imaging
1. Introduction
Cancer is a major public health problem worldwide and lung cancer is the leading cause of
cancer related deaths [1], which has much lower survival rate than other cancers such as breast
cancer [2]. Early diagnosis of cancer is critical, which is expected to contribute significantly to
improve the 5-year survival rates [3].
Many medical imaging methods have been intensively investigated for cancer detection, such
as computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomog-
raphy (PET), and ultrasound. They have some drawbacks, such as, expensive and insufficient
sensitivity to detect early-stage cancers. CT is the current gold standard medical imaging tool
for diagnosis of lung disease, which able to study some features of biological objects such as
lesion size, morphological lesion characterization, and follow-up of lesion growth. However, it
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produces unsafe radiations which may increase cancer risk [4]. To solve this problem, LDCT
with lower radiation has been applied for imaging of lung [5]. However, LDCT is associated
with high false positive rate (up to 96.4%) [6], this may increase morbidity from unnecessary
surgical treatment and also serious psychological burden to the subjects. 18F-Fluorodeoxyglucose
PET/CT has been applied in oncological imaging without achieve reliable results [7, 8]. Table 1
demonstrates the conventional medical imaging methods for lung diseases detection [9].
Recently, electromagnetic tomography (EMT) has been proposed as a promising tool for diagno-
sis of early-stage diseases such as lung and brain due to its low-cost and high-sensitivity [10].
Biopsy is another common method to distinguish cancerous and benign tissues, but it is expen-
sive and requires trained physicians [11]. Cytokeratin 21-1 (CYFRA21-1) is a sensitive and
specific marker for non-small cell lung cancer (NSCLC), especially in squamous cell carcinoma
[12]. Biosensors are analytical devices to identify a target sequence by hybridization with com-
plementary probes immobilized on a solid substrate. Biosensors have attracted increased atten-
tion due to they have many advantages such as low-cost, easy-to-use and easy to fabricate. Over
the past few years, various nanoparticles have been applied to develop biosensors to increase the
sensitivity. Other factors affect stability, reproducibility, and sensitivity, including electrode
design and probe immobilization. However, biosensor-based approaches are time-consuming
and less sensitive for the low marker concentrations at early stages [13]. Therefore, developing a
high-sensitivity label-free method for rapid diagnosis of lung diseases is urgently needed.
This paper describes the recent achievements on bio-imaging and bio-sensing approaches for
identifying lung cancer. Recent trends in EMT and bio-sensing methods are also reviewed.
Several EMT sensor systems, including benefits, limitations, and future research directions are
addressed. The rest of this paper is organized as follows: Section 2 describes biomarkers for
lung cancer detection; Section 3 reviews biosensor techniques for target lung markers detec-
tion; Section 4 presents EMT approaches and measurement systems for imaging of biological
tissues; Section 5 presents current trends and future perspectives.
2. Biomarkers for lung cancer detection
Genetic and proteomics-based biomarkers are the two major types of biomarkers, which can be
identified in patients through tumor cells, urine, sputum, blood, or other body fluids [14]. Table 2
Type Advantage Disadvantage Time
Chest X-ray Reliable Ionizing radiation, low sensitivity and specificity, sensitivity drops with
tissue density increases
Few seconds
CT Reliable Expensive, false negative scans, low sensitivity, radiation risks 5 min
MRI Reliable Some types of cancers cannot be detected such as ductal and lobular
carcinoma, expensive
40–60 min
PET Reliable Expensive, need for radioactive substance and sophisticated instrument,
not suitable for subjects with other complications
90–240 min
Table 1. Conventional lung screening methods [9].
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demonstrates the current available biomarkers for lung cancer detection [15–35]. DNA biomarkers
provide useful information on the process of tumor growth but they are insufficient sensitivity to
detect early-stage tumors due to low concentrations of cancer markers [36]. Protein biomarkers
are the major indicator of lung cancer, which can be classified as predictive and prognostic
markers [37]. Predictive protein markers provide information of the particular therapeutic inter-
vention, while prognostic protein markers offer the overall information of the subjects.
2.1. Proteomic biomarkers
Carcinoembryonic antigen (CEA) is the most common proteomic biomarker to distinguish
malignant and benign tissues. Normally, serum level of CEA is about 2.5–5 ng/mL in healthy
subjects [36]. Neuron-specific enolase (NSE) is a useful marker to investigate neuronal differ-
entiation and to visualize the entire nervous and neuroendocrine systems. It exhibits calcium-
dependent manner to perform its functions and needs magnesium as a cofactor for catalysis
and stabilization of the dimer. Serum levels of NSE are related to some diseases such as
Alzheimer, Huntington’s chorea, neuroblastoma, and small cell lung cancer (SCLC). Com-
pared to CEA, NSE is more sensitive and specific serum marker for SCLC [37]. Serum levels
of NSE is higher than 9 ng/mL in patients with lung cancer. The subjects are considered with
SCLS if the levels of NSE are higher than 35 ng/mL. The combination of NSE with other
markers such as CYFRA 21-1 and CEA offered more effective and reliable detection in univar-
iate and multivariate analysis of lung cancers.
Annexin II and enolase 1 (ENO1) are another common lung cancer biomarkers [38].
Chromogranin A (CgA) is an acidic glycoprotein, which belongs to the granin family of
neuroendocrine secretory proteins. The threshold level of CgA is 50 ng/mL in patients with
lung cancer. The serum levels of CgA were much higher in SCLC patients than that in the
control groups, and there was an association between survival time and serum levels of CgA
[39]. SCLC patients observed the best responses, but the percentage of this histological type
composes of only 20% of all patients with lung cancer.
Cytokeratin-19 is the smallest human cytokeratin, which has been recommended as a high
sensitive and specific marker for lung cancer, particularly in NSCLS. All adenocarcinomas tested
have been positive for CYFRA 21-1, which was about 80% of patients with lung cancers [40]. The
specificity and sensitivity of CYFRA 21-1 was found higher than the other protein markers such
Type Biomarker
Proteomic
biomarkers
Annexin II, APOA1, carcinoembryonic antigen (CEA), carbohydrate antigen 125 (CA125),
carbohydrate antigen 19-9 (CA19-9), cytokeratin fragment 21-1 (CYFRA21-1), CD59 glycoprotein,
transthyretin (TTR), GM2 activator protein (GM2AP), haptoglobin-R 2, Ig-free light chain, neuron-
specific enolase (NSE), nitrated ceruloplasmin, plasma kallikrein B1, ProGRP, retinol binding protein
(RBP), squamous cell carcinoma (SCC), vascular endothelial growth factor (VEGF), TPA, tumor
M2-pyruvate kinase, ENO1, Neuroendocrine markers, HER2, TAG-72.3, hnRNP-A2/B1, PCNA,
CD34, c-erbB2, FHIT, CTNNB1, MUC1, Cyclin D1
Gene biomarkers p53, p16, K-ras, microRNAs, miR-21, miR-210, miR-182, miR-31, miR-200b, miR-205, miR-183,
miR-126-3p, miR-30a, miR-30d, miR-486-5p, miR-451a, miR-126-5p, miR-143, miR-145, miR-206,
miR-133b, hsa-mir-155, hsa-let-7a-2, TERT, TERF2, POT1, MiR-449c
Table 2. Lung cancer markers.
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as CEA and squamous cell carcinoma (SCC) to evaluate NSCLS. The combination of CYFRA 21-1
and other proteomic markers could increase the positive results of lung cancers [41].
However, it is difficult to detect lung cancer with the present markers because they are
nonspecific indicators. To improve the accurate, many researchers have investigated the pro-
tein biomarker panel that consists of CEA, retinol binding protein (RBP), R1-antitrypsin (AAT),
and squamous cell carcinoma (SCC) antigen for accurate disease detection [42]. The sensitivity
was also improved by the biomarker panel consists of CEA and some specific biomarkers such
as ENO1, SCC, NSE, CYFRA21-1 [43].
2.2. Gene biomarkers
The p53 protein is not normally detected in healthy lung tissue. Approximately 50% of NSCLC
patients have been reported with p53 mutation, and the spectrum changed between 34% and
82%. p53 expression was observed in about 58% of lung cancer patients [44]. In addition, the
poor correlation relationship between bcl-2 and p53 over-expression was observed in lung
cancer patients [45].
p16 methylation was detected in lung cancer patients, in particularly, in chromate lung cancers
and smokers. p16 methylation was found in approximately 21~51% of NSCLC patients, while
p16 loss of heterozygosity was observed in about 54~100% of NSCLC patients [46, 47].
Ras genes are responsible for the cancer-causing activities of the Harvey (H-ras) and Kirsten
(K-ras) sarcoma viruses. Ras mutations were discovered in lung cancer patients (20~25%) and
patients with specific cancers (up to 90%). Approximately 60% of Ras mutations were confined
to codon 12 of K-ras [48]. K-Ras mutation was also discovered in lung cancer patients (up to
78%) and in patients with NSCLS, pleural effusion, sputum, serum, and bronchoalveolar
lavage fluid [49]. Some telomere-related genes such as telomerase reverse transcriptase (TERT),
telomerase-associated factor 2 (TERF2) and protection of telomeres 1 (POT1) are affected on
lung diseases [50, 51]. The telomeres are the territories of repetitive DNA that exist at the end
of the chromosomes and are responsible for the protection of the chromosome ends.
Tumor growth is associated with silence and overexpression miRNAs, thus overexpress miRNAs
has potential to become a useful clinical diagnostic tool for early lungdiseases detection [52]. Seven
upregulated (miR-21, miR-210, miR-182, miR-31, miR-200b, miR-205 and miR-183) and eight
downregulated (miR-126-3p,miR-30a, miR-30d, miR-486-5p, miR-451a, miR-126-5p,miR-143 and
miR-145)miRNAshavebeen investigated for lungmarker detection [53].Additionally, serummiR-
206 and miR-133b have been considered as potential markers for lung carcinogenesis [51]. High
hsa-mir-155 and low hsa-let-7a-2 can detect lung cancer correctly [54]. MiR-449c with the target
marker c-Myc has been applied for NSCLS, which could suppress cancer cells growth in vivo [55].
3. Biosensors for lung cancer biomarker detection
Table 3 shows some recent developed biosensors for detecting lung tumor markers [56–72].
Fluorescence, interferometric, surface plasmon resonance biosensors (SPR), optrode-based
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fiber, evanescent wave fiber, and resonant mirror biosensors are the main types of optical
biosensors. SPR-based sensors are more attractive for lung cancer markers detection, which
can be classified as label-free and real-time affinity reaction detection systems. A high-
precision optical system was developed to detect CYFRA21-1 based on magnetic enzyme-
linked immunoassay [73]. Experimental results demonstrated that the proposed optical system
has potential to become a powerful tool for rapid diagnostic of lung cancer marker with
several advantages such as compactness, sensitive, and fast. A plasmonic optical fiber
immunosensor was also developed by Ribaut et al. to detect cytokeratin [74]. Their research
findings offered an important milestone towards the clinical detection of biomarkers in tissues.
Quartz is a popular crystal to develop analytic devices such as quartz crystal microbalance
(QCM) sensor. QCM-based sensors can detect point mutation in lung cancer patients [75],
which measure frequency changes in quartz crystal resonators based on adsorbate recognition,
Biomarker Capture agent Sample Transducer Limit of
detection
Linear range Refs.
VEGF VEGFreceptor-1 Serum Electrochemical - 10–70 pg/mL [56]
Aptamer - Electrochemical 15 nM - [57]
VEGF165 Aptamer Serum Fluorescent - 1.25 pM–1.25 μM [58]
LAG3 protein Antibody Plasma SPRi-MALDITOP MS - - [59]
TP53 gene DNA SPR and QCM - 0.3–2 μM [60]
COX-2 Polyclona
antibody
Simulated
blood sample
SPR 1.35  104
ng/mL
3.64x104 –
3.64x102 ng/mL
[61]
Fluorescence 1.02  104
ng/mL
7.46x104 –
7.46x10 ng/mL
CEA Antibody Serum SPR - - [62]
p53 antibody p53 antigen Serum Microcantilever biosensor - 20 ng/mL–
20 μg/mL
[63]
p53 ssDNA - Electrochemiluminescence - - [64]
p53 (wild &
total)
ds-DNA &
antibody
- SPR 10.6 and
1.06 pM
- [65]
EGFR Aptamer Serum Optical - - [66]
CA 19-9 Antibody - SPR 66.7 U/mL - [67]
ALCAM Antibody 10% Serum SPRi 6 ng/mL - [68]
ALCAM &
hCG
antibody 10%Serum SPRi 45–100 ng/
mL
[69]
TAGLN2 Antibody 10%Serum SPRi 3 ng/mL [70]
DNA
mutations
ssDNA Serum SPR 50 nM [71]
K-ras point
mutation
PNA - SPR - [72]
Table 3. The recently developed biosensors for target lung tumor markers detection.
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and the mass changes caused by selective binding can be detected by the corresponding
changes in crystals. The advantages of piezoelectric sensors include easy-to-use, cost-effective,
and sensitive.
Electrochemical biosensors measure the changes of dielectric properties, dimension, shape and
charge distribution while antibody–antigen complex occurred on the electrode surface [76].
Electrochemical biosensors offer high sensitivity and specificity for lung tumor markers detec-
tion. Electrochemical-based transducers generally consists of semiconductors and screen-
printed electrodes for constructing the biosensors, which able to detect molecules such as
proteins, antibody, DNA, antigen and heavy metal ions. The recent advances in electrochemi-
cal nano-biosensors offer promising for diagnosis of molecules with significant benefits in
inexpensive, simplicity, reliability and fast-response, high sensitivity and specificity.
4. Electromagnetic inductance tomography for lung cancer detection
Electromagnetic tomography (EMT) has attracted many attentions worldwide since it offers a
promising alternative to existing medical imaging methods, such as CT or MRI. The approach
uses non-ionizing radiation in the low GHz region of the EM spectrum. EMTapproach is a safe
and cost-effective diagnostic tool and provides structural and functional imaging in one
device. Various EMT approaches have been applied for biomedical imaging with particular
focus on imaging lung, brain, heart, liver tissue and biological tissues [77–90]. Table 4 presents
some recently developed EMT systems.
Watson et al. [91] developed an EMT with phase-stable amplifier for biomedical application.
The phase-stable amplifiers and the gradiometers configurations need not be mutually exclu-
sive, and it was reported that the highest measurement precision could be achieved by utiliz-
ing both approaches. The EMT image quality would be improved by increasing the number of
transmitters and receivers, however, such method also increases the cost, complexity and
operation time of the EMT system. A rotational EMT system containing a transceiver RF coil
was developed for biomedical application. Compared to the conventional systems, the pro-
posed rotational system offered a better field penetration depth towards the center of image.
Semenov et al. [92] investigated the ability of EMT technology to detect brain stroke within a
human head phantom (see Figure 1). The FDTD method was applied to solve the 3D
Frequency Sampling rate Driving level Phase noise
(mo)
Phase drift
(mo)
Linearity
Bath Medical system 10 MHz 100MS/s 30 mA 4 25 R2 = 0.9996
Cardiff Mk2 system [82, 83] 10 MHz 120MS/s 100mArms 9 119 R2 = 0.9998
Craz Mk2 system [84] 50 kHz~ 1.5 MHz 60M/s Max. 200 mA N/A N/A N/A
Glamorgan system [85] 10 MHz N/A N/A N/A 27 N/A
Phillips system [81] 10 MHz 192kS/s 50mArms 12.5 102 R2 = 0.9878
Table 4. Some recently developed EMT systems.
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electromagnetic problem, and the gradient-based approach was used to solve the inverse
problem. The reconstructed images of head phantom are displayed in Figure 2. Their research
findings demonstrated that EMT approach has the potential to become a useful tool for brain
stroke detection in the future.
More recently, Wang et al. [93] proposed a single frequency EMT based approach for small
lung tumor detection in human thorax models. As shown in Figure 3, the system made of 16
coils and each of them worked as both transmitter and receiver. The thorax model was located
in the middle of the tank and was energized with a magnetic field generated by coils located
outside of the tank wall. During data collection, the transmitting coils transmitted EM signals
into the thorax, and the receiving coils measured the scattered magnetic fields from the thorax.
A reconstructed image of the thorax model was obtained using the measured data.
Referring to Figure 3, if a point Q is located within the thorax model, the complex visibility
data for any two coils can be obtained as [94]:
V i, j
!
¼< H
!
scat r
!
i
 
H
!∗
scat r
!
j
 
> (1)
Figure 1. (a) The EMT system developed by Semenov et al. [92]; (b) a photograph of the EMT experimental setup using a
head phantom for the imaging experiment.
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Figure 2. 3D reconstruction of the human head phantom featuring a h-stroke model. Three slices of the real part of the 3D
ε-distribution, (a) axial slice; (b) coronal slice; (c) sagittal slice [92].
Figure 3. (a) The proposed EMT system by Wang et al. [93]; (b) a setup for any pair of coils.
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Where r
!
i and r
!
j denote the coil locations,<>means the time average, Table 3 lists all symbols
and abbreviations. The total complex visibility data of N coils is V
!
¼
PN
i V i, j
!
, N ≥ 3, i 6¼ j.
Define the intensity of thorax as:
I s
!
 
¼
jωμ0
4π
 2
σ sð Þ þ jωε0ε
0
r
 2HT! s!   H∗T! s!0  (2)
If all coils located at the same height, then a 2D image can be reconstructed:
~I l;mð Þ ¼
ðð
V u; vð Þej2π uij lþvijmð Þdudv (3)
Where l ¼ sinθcosϕ and m ¼ sinθsinϕ, uij ¼ xj
!
 xi
!
 
=λ0 and vij ¼ yj
!
 yi
!
 
=λ0, λ0 indicates
the wavelength of free space (see Figure 3).
To study the feasibility of EMT for lung tumor detection, Wang et al. developed a numerical
system using MATLAB software. The system made of 16 circular coils. The electric current
density generated from transmitter was 1A/m2. The finite element approach was applied to
compute the voltage and the measured region was divided into triangular meshes. The work-
ing frequency was 2 MHz. The excitation current density Js
!
was simulated by:
Js
!
¼ ∇ μ10 ∇ A
! 
þ jωσ A
!
(4)
Eq. (4) can be rewritten from Maxwell’s formulas by calculating the total electric field
E
!
¼ jω A
!
∇Ω.
The scattered field measured by any receiver can be modeled as [95]:
H
!
scat r0
!
 
¼
j
4πωμ0
ð
V
Js
!
 ∇
 
 ∇þ k20JM
!
þ jωμ0JS
!
∇
h i
G r
!
; r0
!
 
dV (5)
Where Js
!
¼ jωε0 εr  1ð Þ E
!
, JM
!
¼ jωμ0 μr  1
 	
HT
!
, HT
!
¼ H
!
inc þ H
!
scat.
The following formula can be applied to compute the magnetic field:
H
!
scat r0
!
 
¼
k20
4π
ð
V
a H
!
þb H
!
br br iG br; r0! dVh (6)
Where a ¼ μrεr 
j μr1ð Þ
k0R
1 jk0R
 
, b ¼ μr  1
 	
1þ 3jk0Rþ
3
k0Rð Þ
2
 
, a and b are proportional to
1=R2(i.e. k0R≪ 1). Hence k
2
0a ffi  μr  1
 	
=R2 and k20b ffi 3 μr  1
 	
=R2.
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Born Approximation was applied to solve the forward problem, thus Eq. (6) changes to [90]:
H
!
scat r0
!
 
¼
1
4π
ð
V
μ
r
 1
R
2
 H
!
þ3 H
!
br brh iG r!; r0!ÞdV (7)
Simulation result (see Figure 4) showed that various arbitrary shaped lung tumors with
random sizes and locations could be identified in the thorax images. The proposed EMT
approach offered crucial priority information that can be exploited to improve the capabilities
of diagnostics methods. The advantages of the proposed method include simplified imaging
processing due to the image quantity is proportional to the dielectric properties contrast.
5. Current trends and future perspectives
The current available lung screening approaches are effective but have some limitations as
detailed above. EMT-based approaches have the potential to become an additional or alterna-
tive method to CT for lung disease detection. However, these techniques have some drawbacks,
such as heavy computational imaging algorithm, difficult hardware systems for clinical appli-
cations, and limited spatial resolution. To solve these challenges, many researchers focused on
developing a high dynamic hardware implementation system. Additionally, many investiga-
tors used more coils to improve the image quality. However, such method increases the mutual
coupling signals between coils, which may reduce the detection accuracy. Moreover, the cost
and complexities of the hardware implementation system also increased with increasing the
number of coils. To solve this problem, a single coil could be applied to replace the multi-coil
array. Recent research findings suggested that optimization of coil array configurations offer
some potential benefits in high image resolution, low-cost, and operating time. The multiple-
input-multiple-output techniquemay also help to reduce the complexity of the hardware system.
In the future, more investigations of EMT technique should be taken to improve the image
Figure 4. Simulation result of lung phantom obtained by Wang et al. [93].
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algorithm and hardware implementation system with particular focus on the development of
low-cost and compact RF coils and coil arrays to produce high quality images.
Developing biosensors with implementation of biomarkers have attracted many attentions from
researchers worldwide in the past few years. Up to date, cancer markers are still in discovery
stage and the current evidences are too restricted for early lung cancer detection. Proteomic
biomarkers have been applied within a panel of protein biomarkers but they are not recom-
mended to be used as individual biomarkers for lung cancer detection. Applying individual
marker does not helpful for clinicians to obtain enough information of cancer tissue such as the
stage of cancer, treatment and state of subject. The major problem of biosensor-based techniques is
related to integration of lung cancer detection in primary healthcare. QCM-based biosensors are
more suitable and reliable for clinical surgery compared to other biosensors. The limitations of
biosensors include small target size, marker levels, the possibility of high non-specific binding in
the case of serum or real patient samples. Recent research trends of nano-biosensor techniques for
diagnosis of molecules offer great potential for early lung cancer detection, however, these tech-
niques are not mature for clinical trials. Future investigations should be address directly to
improve the selectivity, sensitivity, accuracy, and multiplexing capacity of biosensors.
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